- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
IMMU Market Currents
more »
-
January 31 Shares of Immunomedics (IMMU) push 3.5% higher premarket after the firm nabs a broad-based patent from the USPTO related to antibody-based products for the treatment of cancer.
Comment![Healthcare, On the Move]
IMMU in Focus
more »
IMMU Related Articles
more »
IMMU News
more »
-
at MarketWatch.com (Aug 24, 2011)
-
at MarketWatch.com (May 17, 2011)
-
at MarketWatch.com (May 13, 2010)
IMMU Press Releases and Filings
more »
-
GlobeNewswire (Fri, 8:30AM)
-
GlobeNewswire (May 10, 2012)
-
GlobeNewswire (May 8, 2012)
-
GlobeNewswire (May 1, 2012)
-
GlobeNewswire (Apr 3, 2012)
IMMU Latest Transcript
more »
Currently, there are no transcripts for IMMU.
IMMU Cramer
more »
Currently, there are no Cramer articles on IMMU.
IMMU Instablog posts
more »
IMMU vs. ETF Alternatives
Company Description
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to... More
